Document Classification

Section Type: RESULTS

Text: At Day 21, both study vaccines induced HI immune responses meeting the US regulatory criteria in subjects 18-64 years (seroprotection rate [SPR] : 98. 0 % [97. 1-98. 6] ; seroconversion rate [SCR] : 89. 7 % [88. 0-91. 2] in the AS03-adjuvanted group ; SPR : 91. 4 % [89. 9-92. 8] ; SCR : 74. 6 % [72. 3-76. 9] in the non-adjuvanted group) and > 64 years of age (SPR : 86. 0 % [82. 5-89. 0] ; SCR : 75. 3 % [71. 1-79. 2] in the AS03-adjuvanted group ; SPR : 69. 1 % [64. 6-73. 3] ; SCR : 56. 7 % [52. 0-61. 3] in the non-adjuvanted group).